VEGF is one of the key elements released by cancer cells for the stimulation of angiogenesis and binds to a receptor on endothelial cells (VEGF-R).[34] Another advantage is that tumor endothelial cells are not malignant, and unlike cancer cells, they do not have preexisting mutations that favor the development of further mutations, which could lead to drug resistance. The gene discussed is VEGFA; the disease is cancer.